Cipla launches cut-price valgancilovir in India
This article was originally published in Scrip
Executive Summary
Cipla has launched valganciclovir, a cut-price generic version of Roche's treatment for cytomegalovirus (CMV) retinitis in AIDS patients, Valcyte, on the Indian market. Cipla had earlier filed a post-grant opposition against Roche's patent for Valcyte in India.